A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Risk factors associated with IgG seropersistence to Chlamydia trachomatis and Mycoplasma genitalium
Tekijät: Koskela, Nea; Butt, Julia; Michels, Birgitta; Syrjänen, Kari; Grenman, Seija; Waterboer, Timo; Syrjänen, Stina; Louvanto, Karolina
Kustantaja: Cambridge University Press
Julkaisuvuosi: 2025
Journal: Epidemiology and Infection
Tietokannassa oleva lehden nimi: Epidemiology and Infection
Artikkelin numero: e104
Vuosikerta: 153
Aloitussivu: 1
Lopetussivu: 7
ISSN: 0950-2688
eISSN: 1469-4409
DOI: https://doi.org/10.1017/S095026882500007X
Verkko-osoite: https://doi.org/10.1017/S095026882500007X
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/499692946
Sexually transmitted infections caused by Chlamydia trachomatis (Ct) and Mycoplasma genitalium (Mg) have significant implications both at the individual and societal levels. Our study evaluated various co-factors associations with persistent serum IgG-antibodies to Ct and Mg. 329 pregnant women and 135 men from the Finnish Family HPV study were analysed for serum IgG-antibodies of pGP3 for Ct and MgPa and rMgPa for Mg using multiplex serology. Seropersistence to both Ct and Mg was more common in women (30.4% and 13.3%) than in men (17.4% and 5.3%). The number of lifetime sexual partners above 10, practice of anal sex, and history of diagnosed Ct were associated with seropersistence to Ct in women, adjusted ORs 5.6 (95%CI 1.39-22.29), 15.3 (95%CI 1.18-197.12) and 18.0 (95%CI 5.59-57.92), respectively. The increasing number of partners before the age f 20 was the main risk factor for seropersistence among women with Mg, adjusted OR range from 5.0 to 12.3 (95%CI range 1.17-100.90) and in men only with 6 to 10 partners for Ct, adjusted OR 12.6 (95%CI 1.55-102.49). To conclude, persistent Ct antibodies were associated with various sexual activities, and Mg seropositivity was mainly associated with increased sexual activity in early 34 adulthood.
Ladattava julkaisu This is an electronic reprint of the original article. |
Julkaisussa olevat rahoitustiedot:
Since its onset in 1998, the FFHPV study has been financially supported by the Academy of Finland
308 [SS, KL]; Päivikki and Sakari Sohlberg Foundation [SS, SG, KL]; Sigrid Jusélius Foundation [KL];
309 and the Finnish Medical Foundation [KL]. The authors declare no conflict of interest.